News
-
-
-
-
COMMUNIQUÉ RÉGLEMENTÉ
Déclaration hebdomadaire d'opérations effectuées du 16 au 20 décembre 2024
-
COMMUNIQUÉ RÉGLEMENTÉ
Disclosure of transactions in own shares from December 16 to December 20, 2024
-
COMMUNIQUÉ DE PRESSE
Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation -
-
-
COMMUNIQUÉ DE PRESSE
Syngenta Group (HK) Holdings Company Limited concludes USD 4,500 million syndicated sustainability-linked term loan facility
Syngenta Group (HK) Holdings Company concludes USD 4,500 million syndicated sustainability-linked term loan facility with banks worldwide. Loan linked to sustainability targets, reflecting company's commitment to innovation and value creation -